Compare Novartis AG (NVS) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Novartis AG trades at $143.84 (market cap $268.57B), while Vanguard Total Stock Market Index Fund ETF trades at $381.05 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 8.6× Novartis AG's market cap, and Novartis AG pays a 3.31% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| NVS | VTI | |
|---|---|---|
Market Cap | $268.57B | $2.30T |
Volume | 1,532,573 | 2,982,924 |
Sector | Health | — |
52-Week High | $168.62 | $384.30 |
52-Week Low | $121.80 | $311.68 |
Typical Hold Time | 82 Days | 131 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VTI trades at $380.52, down slightly by 0.13% with a bullish technical signal from moving averages. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains significant. Recent news highlights long-term growth potential with $500 monthly investments since 2001 growing to approximately $876,000 according to Motley Fool (2026-10-01).
VTI offers diversified U.S. market access with low costs, suitable for long-term investors. Risks include market concentration in top holdings and broader economic sensitivity. Analyst sentiment remains positive for buy-and-hold strategies, though recent articles question the value added by small/mid-cap exposure versus S&P 500-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
